Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV's Immunological Achilles' Heel., PMID:40432047
Structural basis of human cytomegalovirus neutralization by gB AD-5-specific potent antibodies., PMID:40382771
A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice., PMID:40338082
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies., PMID:40202318
Evaluation of Heterologous Prime-boost Vaccine Strategy Using Full-length Cytomegalovirus Glycoprotein B to Trigger BALB/c Mice Immunity., PMID:40052892
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies., PMID:39829861
SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate., PMID:39702373
Perinatal Vaccination by Transamniotic Fetal mRNA Delivery: Immunization Against Human Cytomegalovirus in a Rodent Model., PMID:39389880
The Autonomous Fusion Activity of Human Cytomegalovirus Glycoprotein B Is Regulated by Its Carboxy-Terminal Domain., PMID:39339958
Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation., PMID:39231203
Inhibition of human cytomegalovirus entry into mucosal epithelial cells., PMID:39074588
Human cytomegalovirus glycoprotein variants governing viral tropism and syncytium formation in epithelial cells and macrophages., PMID:38837351
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth., PMID:38378950
Cytokine responses to major human Cytomegalovirus antigens in mouse model., PMID:38359558
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine., PMID:38324766
Nasal Immunization Using Chitosan Nanoparticles with Glycoprotein B of Murine Cytomegalovirus., PMID:38303144
Human cytomegalovirus glycoprotein B genotypic distributions and viral load in symptomatic infants., PMID:38252734
An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study., PMID:38142214
Comparison of methods for the detection of porcine cytomegalovirus/roseolovirus in relation to biosafety monitoring of xenotransplantation products., PMID:38088083
Re-Evaluating Human Cytomegalovirus Vaccine Design: Prediction of T Cell Epitopes., PMID:38005961
Relationship of maternal cytomegalovirus-specific antibody responses and viral load to vertical transmission risk following primary maternal infection in a rhesus macaque model., PMID:37871009
Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection., PMID:37816743
Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis., PMID:37321896
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera., PMID:37310000
In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells., PMID:37266972
Relationship of maternal cytomegalovirus-specific antibody responses and viral load to vertical transmission risk following primary maternal infection in a rhesus macaque model., PMID:37131785
PCR and peptide based PCMV detection in pig - development and application of a combined testing procedure differentiating newly from latent infected pigs., PMID:37120823
The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread., PMID:36823200
Efficiency of CMV serodiagnosis during pregnancy in daily laboratory routine., PMID:36709885
A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus., PMID:36662906
Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas., PMID:35891239
A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice., PMID:35737741
Sequencing of the Viral UL111a Gene Directly from Clinical Specimens Reveals Variants of HCMV-Encoded IL-10 That Are Associated with Altered Immune Responses to HCMV., PMID:35563032
Heterosubtypic, cross-reactive immunity to human Cytomegalovirus glycoprotein B., PMID:35395673
Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts., PMID:35215877
Dominant Antiviral CD8+ T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus., PMID:35154089
Cytomegalovirus may influence vascular endothelial health in Indonesian HIV-infected patients after 5 years on ART., PMID:34763708
Sequencing Directly from Clinical Specimens Reveals Genetic Variations in HCMV-Encoded Chemokine Receptor US28 That May Influence Antibody Levels and Interactions with Human Chemokines., PMID:34704798
Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models., PMID:34393017
Pathogenesis of human cytomegalovirus in the immunocompromised host., PMID:34168328
Mutagenesis of Human Cytomegalovirus Glycoprotein L Disproportionately Disrupts gH/gL/gO over gH/gL/pUL128-131., PMID:34132577
Detection of Genotype-Specific Antibody Responses to Glycoproteins B and H in Primary and Non-Primary Human Cytomegalovirus Infections by Peptide-Based ELISA., PMID:33802390
Polymorphisms of the cytomegalovirus glycoprotein B genotype in patients with Posner-Schlossman syndrome., PMID:33753409
In Utero Human Cytomegalovirus Infection Is Associated With Increased Levels of Putatively Protective Maternal Antibodies in Nonprimary Infection: Evidence for Boosting but Not Protection., PMID:33560335
Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus., PMID:33361306
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus., PMID:33283275
Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans., PMID:33148624
Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection., PMID:32838941
Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step., PMID:32745149
Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB., PMID:32641474
For research use only. Not for human or drug use.
